MBiotech Associate Director, Leigh Revers, publishes a leading article in Molecular Cancer, a peer-reviewed journal specializing in new oncology research
The article is the culmination of an extensive research program begun at Princess Margaret Hospital in 2000. The work, which focuses on the advancement of novel toxin-based biologic compounds as the next wave of specific anti-cancer therapeutics led Drs. Revers and Gariépy (currently a Senior Scientist at the Sunnybrook Research Institute) to found Molecular Templates Inc., a spin-off company of the University Health Network, that was sold last year to an American investor group in Austin, Texas for $2.5MM.